title: Risks and side effects of islet transplantation.
abstract: Islet transplantation can deliver stable glycemic control, relief from recurrent severe hypoglycemia, and insulin independence. Accessing the portal vein via the percutaneous hepatic approach carries the risk of bleeding, and the infusion of islets a risk of portal vein thrombosis. In the long term, common minor problems with immunosuppression are mouth ulcers, diarrhea, and acne. Longer-term risks include malignancy and serious infection, both rare to date in clinical islet transplantation. Sensitization to donor antigens may also occur. The long-term diabetes complications may stabilize, but of this aspect little is known to date. In the short term, there may be some elevation of serum cholesterol and blood pressure, in some patients there has been a decline in renal function, and in a few, acute retinal bleeds. For most, improvement in glucose control with resolution of glycemic lability and hypoglycemia has been a net benefit.
authors.affiliation: Clinical Islet Transplant Program, 2000 College Plaza, 8215 112th Street, Edmonton, Alberta T6G 2C8, Canada. Edmond.Ryan@ualberta.ca
authors.forename: Edmond A
authors.initials: EA
authors.lastname: Ryan
authors.forename: Breay W
authors.initials: BW
authors.lastname: Paty
authors.forename: Peter A
authors.initials: PA
authors.lastname: Senior
authors.forename: A M James
authors.initials: AM
authors.lastname: Shapiro
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000453:epidemiology / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016381:Islets of Langerhans Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications; D012307:Risk Factors
chemical_list: D007166:Immunosuppressive Agents